Trial Profile
An International, Multicenter, Open-label, Long Term Extension Study Evaluating the Safety of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex (EBS)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2020
Price :
$35
*
At a glance
- Drugs Diacerein (Primary)
- Indications Epidermolysis bullosa
- Focus Adverse reactions
- Sponsors Castle Creek Pharmaceuticals
- 23 Jul 2020 Status changed from active, no longer recruiting to completed.
- 18 Jun 2020 This trial is completed in UK, according to European Clinical Trials Database record.
- 15 Jun 2020 This trial is completed in France (Global End Date: 17 Apr 2019), according to European Clinical Trials Database record.